{"id":67946,"date":"2025-10-03T07:00:43","date_gmt":"2025-10-03T07:00:43","guid":{"rendered":"https:\/\/medsbase.com\/?post_type=product&#038;p=67946"},"modified":"2026-04-30T10:23:26","modified_gmt":"2026-04-30T10:23:26","slug":"bdenza","status":"publish","type":"product","link":"https:\/\/medsbase.com\/ro\/product\/bdenza\/","title":{"rendered":"Bdenza"},"content":{"rendered":"<p><!-- medsbase-tldr-answer --><\/p>\n<div style=\"background:#fff8e1;border-left:4px solid #f5a623;padding:18px 22px;margin:0 0 24px 0;border-radius:4px;\">\n<h3 class=\"wp-block-heading\" style=\"margin:0 0 8px 0;font-size:16px;font-weight:700;\">\u26a1 R\u0103spuns rapid \u2014 Ce este Bdenza?<\/h3>\n<p style=\"margin:0;\"><strong>Bdenza<\/strong> este un comprimat oral produs de Beacon Pharmaceuticals care con\u021bine <strong>enzalutamid\u0103 40 mg<\/strong> \u2014 un <strong>inhibitor de semnalizare a receptorului androgen de genera\u021bia a doua<\/strong>. Utilizat\u0103 pentru <strong>cancer de prostat\u0103 metastatic rezistent la castrare (mCRPC)<\/strong>, <strong>CRPC non-metastatic<\/strong> \u0219i <strong>cancer de prostat\u0103 metastatic sensibil la hormoni<\/strong>. Doz\u0103 standard: <strong>160 mg o dat\u0103 pe zi (4 \u00d7 40 mg comprimate)<\/strong>, cu sau f\u0103r\u0103 alimente. Mai puternic dec\u00e2t anti-androgenii de prima genera\u021bie (bicalutamid\u0103, flutamid\u0103) \u0219i activ \u00een boala rezistent\u0103 la castrare unde acestea e\u0219ueaz\u0103. <strong>Risc de convulsii \u2014 evita\u021bi la pacien\u021bii cu istoric de convulsii.<\/strong> Alte riscuri importante: hipertensiune, oboseal\u0103, c\u0103deri\/fracturi, efecte cognitive, sindromul encefalopatiei posterioare reversibile (rar). Continua\u021bi agonistul LHRH concomitent pe tot parcursul tratamentului. Monitorizare obligatorie: TA la baz\u0103 + la fiecare vizit\u0103, teste hepatice periodice + hemogram\u0103 complet\u0103.<\/p>\n<\/div>\n<div class=\"medsbase-trust-strip\" style=\"background:#f4f8fb;border:1px solid #d8e3eb;padding:12px 16px;margin:16px 0;border-radius:4px;font-size:14px;\">\n<strong>Ce beneficii ofer\u0103 MedsBase:<\/strong> Produc\u0103tor certificat WHO-GMP \u00b7 Ambalaj discret \u00b7 Livrare la nivel mondial \u00b7 Peste 1.400 de recenzii verificate <a href=\"https:\/\/medsbase.com\/ro\/reviews\/\">ale clien\u021bilor<\/a>\n<\/div>\n<p class=\"medsbase-reship-line\" style=\"font-size:14px;color:#444;margin:8px 0 18px;\">\ud83d\udce6 Fiecare comand\u0103 este acoperit\u0103 de politica noastr\u0103 de <a href=\"https:\/\/medsbase.com\/ro\/medsbase-re-shipment-assurance-policy\/\"><strong>Politica noastr\u0103 de Reexpediere Garantat\u0103<\/strong><\/a> \u2014 dac\u0103 coletul dumneavoastr\u0103 nu sose\u0219te \u00een 20 de zile lucr\u0103toare, \u00eel relivr\u0103m.<\/p>\n<div style=\"background:#fff3f3;border-left:4px solid #d9534f;padding:14px 18px;margin:0 0 24px 0;border-radius:4px;font-size:14px;\"><strong>\u26a0 Supraveghere specializat\u0103 necesar\u0103.<\/strong> Medicamentele pentru cancer trebuie prescrise de un oncolog tratant, cu un diagnostic confirmat, stadializare ini\u021bial\u0103 \u0219i un plan de tratament definit. Nu \u00eencepe\u021bi, nu opri\u021bi, nu modifica\u021bi doza \u0219i nu utiliza\u021bi medicamente pentru cancer \u00een afara unui plan de \u00eengrijire condus de oncologie. Majoritatea medicamentelor pentru cancer necesit\u0103 monitorizare regulat\u0103 prin analize de s\u00e2nge (hemoleucogram\u0103, teste hepatice, func\u021bie renal\u0103), sunt absolut contraindicate \u00een sarcin\u0103 \u0219i au interac\u021biuni medicamentoase semnificative.<\/div>\n<div style=\"background:#f4f8fb;border:1px solid #d6e4ec;padding:12px 18px;margin:14px 0;border-radius:4px;font-size:14px;color:#3a5160;text-align:center;\">\n<strong>\ud83d\udd12 Checkout criptat<\/strong> \u00b7 <strong>\ud83d\udcb3 Procesor verificat<\/strong> \u00b7 <strong>\ud83d\ude9a Livrare worldwide<\/strong> \u00b7 <strong>\u2b50 4,9\/5 de la peste 1.400 de clien\u021bi<\/strong>\n<\/div>\n<h2 class=\"wp-block-heading\">Ce este Bdenza?<\/h2>\n<p>Bdenza este un comprimat oral de la Beacon Pharmaceuticals care con\u021bine <strong>enzalutamid\u0103 40 mg<\/strong>. Enzalutamida este un <strong>inhibitor al semnaliz\u0103rii receptorului de androgen (AR) de genera\u021bia a doua<\/strong> \u2014 mecanistic distinct de antiandrogenii de prima genera\u021bie (bicalutamida, flutamida). Este autorizat pentru: <strong>cancer de prostat\u0103 metastatic rezistent la castrare (mCRPC)<\/strong> la pacien\u021bii care nu au primit chimioterapie \u0219i dup\u0103 docetaxel; <strong>CRPC non-metastatic<\/strong> cu PSA \u00een cre\u0219tere rapid\u0103; \u0219i <strong>cancerul de prostat\u0103 metastazic sensibil la castrare (mHSPC)<\/strong> cu ADT concomitent.<\/p>\n<h2 class=\"wp-block-heading\">Cum func\u021bioneaz\u0103 Bdenza?<\/h2>\n<p>Enzalutamida este un inhibitor triplu al semnaliz\u0103rii AR:<\/p>\n<ul>\n<li><strong>Legare competitiv\u0103 a AR<\/strong> cu afinitate mult mai mare dec\u00e2t antiandrogenii de prima genera\u021bie.<\/li>\n<li><strong>Inhib\u0103 translocarea nuclear\u0103 a AR<\/strong> \u2014 chiar \u0219i atunci c\u00e2nd este legat de androgen, previne intrarea receptorului \u00een nucleu.<\/li>\n<li><strong>Inhib\u0103 legarea AR-ADN<\/strong> \u2014 chiar dac\u0103 AR intr\u0103 \u00een nucleu, previne legarea la elementele de r\u0103spuns androgen pe genele \u021bint\u0103.<\/li>\n<\/ul>\n<p>Acest mecanism triplu face enzalutamida activ\u0103 \u00een <strong>cancerul de prostat\u0103 rezistent la castrare<\/strong>, unde supraexprimarea AR \u0219i variantele de splicing AR fac anti-androgenii de prim\u0103 genera\u021bie ineficien\u021bi.<\/p>\n<h2 class=\"wp-block-heading\">Utiliz\u0103ri \u0219i indica\u021bii<\/h2>\n<ul>\n<li><strong>Cancer de prostat\u0103 metastatic rezistent la castrare (mCRPC)<\/strong> \u2014 f\u0103r\u0103 chimioterapie anterioar\u0103 (PREVAIL) \u0219i post-docetaxel (AFFIRM)<\/li>\n<li><strong>CRPC non-metastatic cu timp de dublare a PSA &lt; 10 luni<\/strong> (PROSPER)<\/li>\n<li><strong>Cancer de prostat\u0103 metastatic sensibil la hormoni (mHSPC)<\/strong> cu ADT (ARCHES, ENZAMET)<\/li>\n<\/ul>\n<h2 class=\"wp-block-heading\">Doza Bdenza \u0219i cum s\u0103 lua\u021bi<\/h2>\n<p>Doza standard: <strong>160 mg o dat\u0103 pe zi (4 \u00d7 40 mg comprimate) la aceea\u0219i or\u0103 \u00een fiecare zi<\/strong>, cu sau f\u0103r\u0103 m\u00e2ncare.<\/p>\n<ol>\n<li>\u00cenghi\u021bi\u021bi comprimatele \u00eentregi cu ap\u0103. NU mesteca\u021bi, nu dizolva\u021bi \u0219i nu despica\u021bi.<\/li>\n<li>Continua\u021bi terapia concomitent\u0103 cu agonist LHRH pe tot parcursul tratamentului cu enzalutamid\u0103, cu excep\u021bia cazului \u00een care a\u021bi fost castrat chirurgical.<\/li>\n<li><strong>Monitorizare obligatorie:<\/strong> tensiune arterial\u0103 la ini\u021biere \u0219i la fiecare vizit\u0103 clinic\u0103; teste hepatice (LFTs) \u0219i hemogram\u0103 (FBC) periodic; PSA la fiecare 3 luni.<\/li>\n<li><strong>Prevenirea c\u0103derilor \u0219i a fracturilor:<\/strong> pacien\u021bii \u00een v\u00e2rst\u0103 au risc crescut de c\u0103dere \u0219i fractur\u0103 sub enzalutamid. Evaluare a s\u0103n\u0103t\u0103\u021bii osoase, calciu + vitamina D, se poate lua \u00een considerare un bisfosfonat.<\/li>\n<li><strong>Modific\u0103ri ale dozei<\/strong> pentru insuficien\u021b\u0103 hepatic\u0103 moderat\u0103, evenimente adverse severe sau toxicitate grad \u2265 3: reduce\u021bi la 80 sau 120 mg\/zi sub \u00eendrumare specializat\u0103.<\/li>\n<li>Nu \u00eentrerupe\u021bi f\u0103r\u0103 instruc\u021biuni de la oncolog.<\/li>\n<\/ol>\n<h2 class=\"wp-block-heading\">Efecte Secundare Bdenza<\/h2>\n<p><strong>Frecvente:<\/strong> oboseal\u0103 (efectul secundar dominant), valuri de c\u0103ldur\u0103, hipertensiune, risc de c\u0103dere \u0219i fractur\u0103 (la v\u00e2rstnici), artralgie, cefalee, ame\u021beli, sc\u0103dere \u00een greutate, anxietate, insomnie.<\/p>\n<p><strong>Important:<\/strong><\/p>\n<ul>\n<li><strong>Criz\u0103 epileptic\u0103 (&lt;1% \u00een studii)<\/strong> \u2014 scade pragul convulsiilor; evita\u021bi la pacien\u021bii cu istoric de crize epileptice sau care iau medicamente care scad pragul convulsiilor<\/li>\n<li>Efecte cognitive: dificult\u0103\u021bi de memorie, tulbur\u0103ri de concentrare<\/li>\n<li>Hipertensiune arterial\u0103 \u2014 debut sau agravare; trata\u021bi agresiv<\/li>\n<li>Sindromul de encefalopatie posterioar\u0103 reversibil\u0103 (PRES) \u2014 rar dar documentat; cefalee sever\u0103 de debut, confuzie, tulbur\u0103ri de vedere, convulsii<\/li>\n<li>Hepatotoxicitate (cre\u0219teri minore ale enzimelor hepatice frecvente; forme severe rare)<\/li>\n<li>Neutropenie, anemie<\/li>\n<\/ul>\n<h2 class=\"wp-block-heading\">Avertismente \u0219i precau\u021bii<\/h2>\n<ul>\n<li><strong>Istoric de convulsii (orice tip):<\/strong> evita\u021bi enzalutamid. Dac\u0103 esen\u021bial, supraveghere specializat\u0103 neurologie + oncologie.<\/li>\n<li><strong>Medicamente care scad pragul convulsiilor<\/strong> (bupropion, clozapin\u0103, tramadol, fluoroquinolone, teofilin\u0103): precau\u021bie.<\/li>\n<li><strong>Risc de c\u0103deri \u0219i fracturi:<\/strong> evaluarea s\u0103n\u0103t\u0103\u021bii osoase, \u00eengrijire suportiv\u0103.<\/li>\n<li><strong>Hipertensiune arterial\u0103:<\/strong> monitorizare tensiune arterial\u0103 ini\u021bial\u0103 \u0219i continu\u0103.<\/li>\n<li><strong>Insuficien\u021b\u0103 hepatic\u0103 sever\u0103 (Child-Pugh C):<\/strong> nu este recomandat.<\/li>\n<li><strong>Simptome PRES:<\/strong> cefalee sever\u0103 nou\u0103, modific\u0103ri ale vederii, confuzie \u2014 \u00eentrerupe\u021bi \u0219i cere\u021bi evaluare \u00een aceea\u0219i zi.<\/li>\n<li><strong>Sarcina \/ fertilitate:<\/strong> indica\u021bie doar pentru b\u0103rba\u021bi. Utiliza\u021bi prezervativ + contracep\u021bie la partenerii de sex feminin cu poten\u021bial de reproducere \u00een timpul tratamentului + 3 luni dup\u0103.<\/li>\n<\/ul>\n<h2 class=\"wp-block-heading\">Interac\u021biuni medicamentoase<\/h2>\n<table style=\"border-collapse:collapse;width:100%;margin:12px 0;\">\n<thead>\n<tr style=\"background:#2c7cb0;color:#fff;\">\n<th style=\"padding:10px;border:1px solid #ddd;\">Combina\u021bi cu<\/th>\n<th style=\"padding:10px;border:1px solid #ddd;\">Efect<\/th>\n<th style=\"padding:10px;border:1px solid #ddd;\">Ce s\u0103 face\u021bi<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td style=\"padding:10px;border:1px solid #ddd;\">Inhibitori puternici ai CYP2C8 (gemfibrozil)<\/td>\n<td style=\"padding:10px;border:1px solid #ddd;\">Cre\u0219te nivelul enzalutamid\u0103 \u2014 risc de toxicitate<\/td>\n<td style=\"padding:10px;border:1px solid #ddd;\">Reduce\u021bi enzalutamida la 80 mg\/zi dac\u0103 asocierea este inevitabil\u0103.<\/td>\n<\/tr>\n<tr>\n<td style=\"padding:10px;border:1px solid #ddd;\">Inductori puternici ai CYP3A4 (rifampicin\u0103, carbamazepin\u0103, fenitoin\u0103, sun\u0103toare)<\/td>\n<td style=\"padding:10px;border:1px solid #ddd;\">Sc\u0103derea nivelului enzalutamid\u0103 \u2014 e\u0219ec terapeutic<\/td>\n<td style=\"padding:10px;border:1px solid #ddd;\">Evita\u021bi. Dac\u0103 este inevitabil, cre\u0219te\u021bi la 240 mg\/zi sub \u00eendrumare specializat\u0103.<\/td>\n<\/tr>\n<tr>\n<td style=\"padding:10px;border:1px solid #ddd;\">Warfarin \u0219i alte substraturi CYP2C9 \/ CYP3A4 cu indice terapeutic \u00eengust<\/td>\n<td style=\"padding:10px;border:1px solid #ddd;\">Enzalutamida este un inductor puternic al CYP3A4 \u2014 scade nivelul multor medicamente<\/td>\n<td style=\"padding:10px;border:1px solid #ddd;\">Schimba\u021bi warfarinul cu un DOAC (apixaban, edoxaban) sau monitoriza\u021bi INR s\u0103pt\u0103m\u00e2nal.<\/td>\n<\/tr>\n<tr>\n<td style=\"padding:10px;border:1px solid #ddd;\">Medicamente care scad pragul convulsiv (bupropion, tramadol, clozapin\u0103, fluorochinolone, teofilin\u0103)<\/td>\n<td style=\"padding:10px;border:1px solid #ddd;\">Risc crescut de convulsii<\/td>\n<td style=\"padding:10px;border:1px solid #ddd;\">Evita\u021bi acolo unde este posibil.<\/td>\n<\/tr>\n<tr>\n<td style=\"padding:10px;border:1px solid #ddd;\">Agoni\u0219ti LHRH (goserelin, leuprorelin)<\/td>\n<td style=\"padding:10px;border:1px solid #ddd;\">Terapie de baz\u0103 standard<\/td>\n<td style=\"padding:10px;border:1px solid #ddd;\">Continua\u021bi pe tot parcursul tratamentului cu enzalutamid\u0103.<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<h2 class=\"wp-block-heading\">Depozitare<\/h2>\n<ul>\n<li>Depozita\u021bi la temperatura camerei, 15\u201330\u00b0C.<\/li>\n<li>P\u0103stra\u021bi la distan\u021b\u0103 de copii, femei \u00een v\u00e2rst\u0103 fertil\u0103 \u0219i animale de companie.<\/li>\n<\/ul>\n<h2 class=\"wp-block-heading\">Alternative conexe pe MedsBase<\/h2>\n<p>Alte medicamente oncologice disponibile \u00eempreun\u0103 cu acest produs:<\/p>\n<ul>\n<li><a href=\"https:\/\/medsbase.com\/ro\/bicalumutide\/\"><strong>Bicalumutid\u0103 (bicalutamid\u0103 50 mg)<\/strong><\/a><\/li>\n<li><a href=\"https:\/\/medsbase.com\/ro\/cytomid\/\"><strong>Cytomid (flutamid\u0103 250 mg)<\/strong><\/a><\/li>\n<\/ul>\n<p><a href=\"https:\/\/medsbase.com\/ro\/anti-cancer-medication\/\">R\u0103sfoi\u021bi toate medicamentele anti-cancer \u2192<\/a><\/p>\n<p><!-- medsbase-why-order --><\/p>\n<h3>De ce s\u0103 comanzi de la MedsBase<\/h3>\n<p>Fiecare lot este procurat de la un <strong>produc\u0103tor certificat WHO-GMP<\/strong>. Comenzile sunt expediate \u00een ambalaje simple, f\u0103r\u0103 marc\u0103, de la partenerii no\u0219tri de onorare \u0219i acoperite de <a href=\"\/ro\/medsbase-re-shipment-assurance-policy\/\">Politica noastr\u0103 de Reexpediere Garantat\u0103<\/a>: dac\u0103 un colet nu ajunge \u00een 20 de zile lucr\u0103toare, trimitem gratuit o nou\u0103 comand\u0103, f\u0103r\u0103 \u00eentreb\u0103ri.<\/p>\n<p><!-- medsbase-related-alts-v1 --><\/p>\n<h3 class=\"wp-block-heading\">Medicamente Anticanceroase Asem\u0103n\u0103toare<\/h3>\n<p>Alte medicamente oncologice disponibile \u00eempreun\u0103 cu acest produs:<\/p>\n<ul>\n<li><a href=\"https:\/\/medsbase.com\/ro\/bicalumutide\/\">Bicalumutid\u0103 (bicalutamid\u0103 50 mg)<\/a><\/li>\n<li><a href=\"https:\/\/medsbase.com\/ro\/cytomid\/\">Cytomid (flutamid\u0103 250 mg)<\/a><\/li>\n<li><a href=\"https:\/\/medsbase.com\/ro\/endace\/\">Endace (megestrol 40\/160 mg)<\/a><\/li>\n<li><a href=\"https:\/\/medsbase.com\/ro\/tamilong\/\">Tamilong (tamoxifen 10\/20 mg)<\/a><\/li>\n<li><a href=\"https:\/\/medsbase.com\/ro\/votrient\/\">Votrient (pazopanib 200\/400 mg)<\/a><\/li>\n<\/ul>\n<h2 id=\"faqs\">\u00centreb\u0103ri frecvente<\/h2>\n<h3 class=\"wp-block-heading\">Cum difer\u0103 Bdenza de bicalutamid\u0103 sau flutamid\u0103?<\/h3>\n<p>Enzalutamide este un <strong>inhibitor de genera\u021bia a doua<\/strong> al semnaliz\u0103rii AR cu trei mecanisme (legare AR + blocare translocare nuclear\u0103 AR + blocare legare AR-ADN) fa\u021b\u0103 de mecanismul unic al medicamentelor de prima genera\u021bie. Implica\u021bia clinic\u0103: <strong>enzalutamide func\u021bioneaz\u0103 \u00een boala rezistent\u0103 la castrare<\/strong> unde bicalutamida \u0219i flutamida au e\u0219uat. Este de asemenea mai potent \u0219i produce r\u0103spunsuri PSA mai profunde, dar cu mai multe efecte adverse cognitive, hipertensiune \u0219i risc de c\u0103dere.<\/p>\n<h3 class=\"wp-block-heading\">De ce este istoricul de convulsii o contraindica\u021bie?<\/h3>\n<p>Enzalutamide traverseaz\u0103 bariera hemato-encefalic\u0103 \u0219i scade pragul convulsiilor. \u00cen studii, inciden\u021ba convulsiilor a fost &lt; 1%, dar a crescut la pacien\u021bii cu factori predispozan\u021bi. Evita\u021bi enzalutamida la orice pacient cu antecedente de convulsii (orice tip), metastaze cerebrale sau medicamente concomitente care scad pragul convulsiilor (bupropion, tramadol, clozapin\u0103, fluoroquinolone, teofilin\u0103). Dac\u0103 enzalutamida este esen\u021bial\u0103 la un astfel de pacient, speciali\u0219tii \u00een neurologie \u0219i oncologie trebuie s\u0103 fie de acord asupra raportului risc-beneficiu.<\/p>\n<h3 class=\"wp-block-heading\">Va trebui s\u0103 \u00eentrerup terapia de deprivare androgen\u0103 (agonist LHRH) c\u00e2nd \u00eencep Bdenza?<\/h3>\n<p>Nu \u2014 continua\u021bi agonistul LHRH (goserelin\u0103, leuprorelin\u0103 etc.) pe tot parcursul tratamentului cu enzalutamid\u0103. Combina\u021bia dintre castrarea de fond \u0219i inhibarea semnaliz\u0103rii AR este esen\u021bial\u0103. \u00centreruperea agonistului LHRH permite recuperarea testosteronului, ceea ce poate anula efectul enzalutamidei.<\/p>\n<h3 class=\"wp-block-heading\">De ce este oboseala at\u00e2t de frecvent\u0103 la Bdenza?<\/h3>\n<p>Oboseala este cel mai frecvent \u0219i semnificativ efect secundar din punct de vedere clinic \u2014 afect\u00e2nd aproximativ 35% dintre pacien\u021bi \u00een studii. Cauza este multifactorial\u0103: deprivare androgen\u0103 profund\u0103, posibile efecte directe asupra SNC, anemie. Se poate gestiona prin exerci\u021biu structurat (contraintuitiv eficient), igien\u0103 somnific\u0103 bun\u0103, screening \u0219i tratament al anemiei, \u0219i considerarea reducerii de doz\u0103 (160 \u2192 120 mg\/zi) dac\u0103 este intolerabil.<\/p>\n<h3 class=\"wp-block-heading\">Ce este PRES \u0219i cum \u00eel recunosc?<\/h3>\n<p>Sindromul encefalopatiei posterioare reversibile (PRES) este o complica\u021bie rar\u0103 dar documentat\u0103 a enzalutamidei caracterizat\u0103 prin <strong>cefalee sever\u0103, confuzie, modific\u0103ri vizuale (orbire cortical\u0103), crize epileptice \u0219i alterarea st\u0103rii de con\u0219tien\u021b\u0103<\/strong>. \u00centrerupe\u021bi imediat enzalutamida \u0219i solicita\u021bi evaluare medical\u0103 \u00een aceea\u0219i zi pentru oricare dintre aceste simptome. Majoritatea cazurilor se rezolv\u0103 prin \u00eentreruperea medicamentului, dar recunoa\u0219terea la timp previne leziuni neurologice permanente.<\/p>\n<h3 class=\"wp-block-heading\">Exist\u0103 multe interac\u021biuni medicamentoase de care trebuie s\u0103 m\u0103 \u00eengrijorez?<\/h3>\n<p>Da \u2014 enzalutamida este un <strong>inducer puternic al CYP3A4<\/strong> \u0219i reduce nivelul sanguin al multor medicamente co-prescrise. Cele mai importante din punct de vedere clinic: <strong>warfarin<\/strong> (trecere la un DOAC sau verificare INR s\u0103pt\u0103m\u00e2nal\u0103), <strong>anticoagulante orale directe<\/strong> (evaluare specialist), unele statine, unele antihipertensive, opioide, unele antiepileptice. Spune\u021bi fiec\u0103rui medic c\u0103 lua\u021bi enzalutamid\u0103.<\/p>\n<h3 class=\"wp-block-heading\">Pot conduce pe Bdenza?<\/h3>\n<p>Pruden\u021b\u0103 \u2014 oboseala, ame\u021belile \u0219i (rar) crizele epileptice pot afecta capacitatea de conducere. Majoritatea pacien\u021bilor se adapteaz\u0103 \u0219i conduc \u00een siguran\u021b\u0103 dup\u0103 primele c\u00e2teva s\u0103pt\u0103m\u00e2ni. Evita\u021bi condusul sau operarea ma\u0219inilor dac\u0103 experimenta\u021bi oboseal\u0103 semnificativ\u0103, ame\u021beli sau orice simptome cognitive.<\/p>\n<h3 class=\"wp-block-heading\">Bdenza vs abirateron\u0103 \u2014 care este mai bun?<\/h3>\n<p>Ambele reprezint\u0103 op\u021biuni de linia a doua dup\u0103 e\u0219ecul antiandrogenelor de prim\u0103 genera\u021bie. Datele comparative sunt limitate; alegerea depinde de preferin\u021bele privind efectele secundare \u0219i comorbidit\u0103\u021bi. <strong>Enzalutamide:<\/strong> oboseal\u0103 mai accentuat\u0103, efecte cognitive, hipertensiune, risc de c\u0103dere; nu necesit\u0103 co-prescriere de steroizi. <strong>Abirateron\u0103:<\/strong> necesit\u0103 administrare concomitent\u0103 de prednison 5 mg de dou\u0103 ori pe zi; hipertensiune \u0219i reten\u021bie de lichide mai frecvente; poate agrava controlul diabetic. Discuta\u021bi cu oncologul dumneavoastr\u0103.<\/p>","protected":false},"excerpt":{"rendered":"<p>\u2705 \u00cencetine\u0219te progresia cancerului<br \/>\n\u2705 Reduce cre\u0219terea tumorii<br \/>\n\u2705 \u00cembun\u0103t\u0103\u021be\u0219te rezultatele de supravie\u021buire<br \/>\n\u2705 Sprijin\u0103 tratamentul prostatic<br \/>\n\u2705 \u00cembun\u0103t\u0103\u021be\u0219te calitatea vie\u021bii<\/p>\n<p><strong>Bdenza<\/strong> con\u021bine <strong>Enzalutamide<\/strong> 40 mg.<\/p>","protected":false},"featured_media":67947,"comment_status":"open","ping_status":"closed","template":"","meta":[],"product_brand":[],"product_cat":[3595],"product_tag":[5422,5423],"class_list":{"0":"post-67946","1":"product","2":"type-product","3":"status-publish","4":"has-post-thumbnail","6":"product_cat-anti-cancer-medication","7":"product_tag-bdenza","8":"product_tag-enzalutamide","10":"first","11":"instock","12":"shipping-taxable","13":"purchasable","14":"product-type-variable","15":"has-default-attributes"},"acf":[],"_links":{"self":[{"href":"https:\/\/medsbase.com\/ro\/wp-json\/wp\/v2\/product\/67946","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/medsbase.com\/ro\/wp-json\/wp\/v2\/product"}],"about":[{"href":"https:\/\/medsbase.com\/ro\/wp-json\/wp\/v2\/types\/product"}],"replies":[{"embeddable":true,"href":"https:\/\/medsbase.com\/ro\/wp-json\/wp\/v2\/comments?post=67946"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/medsbase.com\/ro\/wp-json\/wp\/v2\/media\/67947"}],"wp:attachment":[{"href":"https:\/\/medsbase.com\/ro\/wp-json\/wp\/v2\/media?parent=67946"}],"wp:term":[{"taxonomy":"product_brand","embeddable":true,"href":"https:\/\/medsbase.com\/ro\/wp-json\/wp\/v2\/product_brand?post=67946"},{"taxonomy":"product_cat","embeddable":true,"href":"https:\/\/medsbase.com\/ro\/wp-json\/wp\/v2\/product_cat?post=67946"},{"taxonomy":"product_tag","embeddable":true,"href":"https:\/\/medsbase.com\/ro\/wp-json\/wp\/v2\/product_tag?post=67946"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}